There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CTI BioPharma (CTIC – Research Report), Oncternal Therapeutics (ONCT – Research Report) and Minerva Neurosciences (NERV – Research Report) with bullish sentiments. CTI BioPharma (CTIC) BTIG analyst Robert Hazlett maintained a Buy rating on CTI BioPharma yesterday and set a price target of $10.00. The company's shares closed last Wednesday at $4.68, close to its 52-week high of $5.25. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of -30.8% and a 19.0% success rate.
https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-cti-biopharma-ctic-oncternal-therapeutics-onct?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022 Click aqui para mais gráficos Oncternal Therapeutics.